Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

923 - Computed tomography liver spleen ratio as predictive marker of liver injury in early breast cancer receiving neoadjuvant therapy from 2010-2016. (76P)

Date

18 Nov 2017

Session

Poster lunch

Topics

Cytotoxic Therapy;  Supportive Care and Symptom Management;  Staging Procedures (not Imaging);  Breast Cancer

Presenters

AMABELLE TRINA Gerona

Citation

Annals of Oncology (2017) 28 (suppl_10): x16-x24. 10.1093/annonc/mdx655

Authors

A.T.B. Gerona

Author affiliations

  • Medical Oncology, ST. Luke's Medical Center, 1100 - Manila/PH
More

Resources

Abstract 923

Background

There is no way of predicting who among our early breast cancer patients develop liver injury during neoadjuvant treatment. It is our aim to determine such event by determining Computed tomography liver spleen ratio (LS ratio) and comparing it to liver function test.

Methods

Retrospective review in the Philippines for Stage I-III invasive breast cancer. Computed tomography LS ratio was reviewed by one radiologist. LS ratio cut off values were tested of their accuracy in terms of sensitivity, specificity, negative, and positive predictive values wherein a computed AUC of > 0.70 is considered significantly valid predictive markers.

Results

Total of 35 patients with average age of 53.91 years old, 57% had stage IIIB cancer. Patients’ average liver spleen ratio was 1.10±0.30 at the start, then, it slightly increased towards the end of the treatment (1.13±0.32). SGPT (37.43 to 35.09, p = 0.479) changed from start to end of treatment. Higher rates of liver injury at the start of treatment were as follows, 1(100%) with DOCETAXEL-TRASTUZUMAB, FAC (1,100%), and TAC (1, 11.1%). End of treatment, liver injury were noted among those with AC (1,50%), FAC (1,100%), EPIRUBICIN, DOCETAXEL (1,25%), and TAC (1,11.1%). Liver spleen ratio is significantly correlated with SGPT (r= -0.541, p = 0.001). At end of treatment, LS ratio is correlated with SGPT (r = -0.464, p = 0.005). LS ratio has higher sensitivity at start of treatment 100% at cut off 0.52, while at end of treatment the cut off was 0.87 has higher sensitivity (100%) in predicting liver injury. Based on AUC, LS ratio at the end of treatment showed higher accuracy (AUC =0.597) indicating the LS ratio can be utilized as marker for predicting liver injury.

Conclusions

Higher rates of liver injury at the start of treatment were seen those given Docetaxel- Trastuzumab, FAC and TAC. No liver injury for patients with hormonal treatment. End of treatment, liver injury seen in receiving anthracycline- based regimen. Liver spleen ratio is significantly correlated with SGPT. LS ratio at the end of treatment showed higher accuracy indicating the LS ratio be utilized as marker for predicting liver injury.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.